Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today ...

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

为探究创伤性股腘动脉损伤患者再血管化后缺血性肌肉后遗症（IG）的发生情况及相关危险因素，河北医科大学第三医院研究人员开展回顾性队列研究。结果显示，挤压伤、HCT、CKMB 是独立预测因素，据此构建的列线图预测能力良好，有助于临床预测风险。 创伤在全球范围内是一个严峻的公共卫生问题，其中血管损伤虽占比相对较低，仅为 0.65 - 1.14%，但却不容小觑。下肢动脉损伤在所有外周动脉损伤中约占 30 ...

-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S.